Baird Maintains Outperform on Cellectis, Lowers Price Target to $8
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Baird analyst Jack Allen maintains Cellectis (NASDAQ:CLLS) with a Outperform and lowers the price target from $10 to $8.
Baird analyst Jack Allen maintains Cellectis (NASDAQ:CLLS) with a Outperform and lowers the price target from $10 to $8.